{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:23:00Z","timestamp":1791339780632,"version":"4.3.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-80674-x","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T14:52:51Z","timestamp":1736520771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["GC1126A, a novel ADAMTS13 mutein, evades autoantibodies in immune-mediated thrombotic thrombocytopenic purpura"],"prefix":"10.1038","volume":"15","author":[{"given":"Heechun","family":"Kwak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gahee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngeun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaemok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangbin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spero","family":"Cataland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunghyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Mee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Ja","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"80674_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/B978-0-12-385504-6.00003-8","volume":"99","author":"S Lancellotti","year":"2011","unstructured":"Lancellotti, S. & De Cristofaro, R. Structure and proteolytic properties of ADAMTS13, a metalloprotease involved in the pathogenesis of thrombotic microangiopathies. Prog. Mol. Biol. Transl. Sci. 99, 105\u2013144. https:\/\/doi.org\/10.1016\/B978-0-12-385504-6.00003-8 (2011).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"20","key":"80674_CR2","doi-asserted-by":"publisher","first-page":"7804","DOI":"10.3390\/ijms21207804","volume":"21","author":"S Okhota","year":"2020","unstructured":"Okhota, S., Melnikov, I., Avtaeva, Y., Kozlov, S. & Gabbasov, Z. Shear stress-induced activation of von willebrand factor and cardiovascular pathology. Int. J. Mol. Sci. 21(20), 7804. https:\/\/doi.org\/10.3390\/ijms21207804 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"80674_CR3","doi-asserted-by":"publisher","first-page":"e2013046","DOI":"10.4084\/MJHID.2013.046","volume":"5","author":"A Rauch","year":"2013","unstructured":"Rauch, A. et al. On the versatility of von Willebrand factor. Mediterr J Hematol Infect Dis 5, e2013046. https:\/\/doi.org\/10.4084\/MJHID.2013.046 (2013).","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"80674_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/17474086.2019.1611423","volume":"12","author":"BS Joly","year":"2019","unstructured":"Joly, B. S., Coppo, P. & Veyradier, A. An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev. Hematol. 12(6), 383\u2013395. https:\/\/doi.org\/10.1080\/17474086.2019.1611423 (2019).","journal-title":"Expert Rev. Hematol."},{"issue":"21","key":"80674_CR5","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly, B. S., Coppo, P. & Veyradier, A. Thrombotic thrombocytopenic purpura. Blood 129(21), 2836\u20132846. https:\/\/doi.org\/10.1182\/blood-2016-10-709857 (2017).","journal-title":"Blood"},{"issue":"22","key":"80674_CR6","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","volume":"339","author":"H-M Tsai","year":"1998","unstructured":"Tsai, H.-M. & Lian, E.C.-Y. Antibodies to von willebrand factor\u2013cleaving protease in acute thrombotic thrombocytopenic purpura. New England J. Med. 339(22), 1585\u20131594. https:\/\/doi.org\/10.1056\/NEJM199811263392203 (1998).","journal-title":"New England J. Med."},{"issue":"22","key":"80674_CR7","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","volume":"339","author":"M Furlan","year":"1998","unstructured":"Furlan, M. et al. von willebrand factor\u2013cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic\u2013uremic syndrome. New England J. Med. 339(22), 1578\u20131584. https:\/\/doi.org\/10.1056\/NEJM199811263392202 (1998).","journal-title":"New England J. Med."},{"issue":"20","key":"80674_CR8","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","volume":"116","author":"JN George","year":"2010","unstructured":"George, J. N. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 116(20), 4060\u20134069. https:\/\/doi.org\/10.1182\/blood-2010-07-271445 (2010).","journal-title":"Blood"},{"issue":"6","key":"80674_CR9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi, F. et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. New England J. Med. 374(6), 511\u2013522. https:\/\/doi.org\/10.1056\/NEJMoa1505533 (2016).","journal-title":"New England J. Med."},{"issue":"4","key":"80674_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","volume":"130","author":"F Alwan","year":"2017","unstructured":"Alwan, F. et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood 130(4), 466\u2013471. https:\/\/doi.org\/10.1182\/blood-2016-12-758656 (2017).","journal-title":"Blood"},{"issue":"4","key":"80674_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully, M. et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. New England J. Med. 380(4), 335\u2013346. https:\/\/doi.org\/10.1056\/NEJMoa1806311 (2019).","journal-title":"New England J. Med."},{"issue":"10","key":"80674_CR12","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1055\/s-0038-1668545","volume":"118","author":"T Falter","year":"2018","unstructured":"Falter, T. et al. Relapse rate in survivors of acute autoimmune thrombotic thrombocytopenic purpura treated with or without rituximab. Thromb. Haemost. 118(10), 1743\u20131751. https:\/\/doi.org\/10.1055\/s-0038-1668545 (2018).","journal-title":"Thromb. Haemost."},{"issue":"3","key":"80674_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood.2022017023","volume":"141","author":"AJ Doyle","year":"2023","unstructured":"Doyle, A. J. et al. Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy. Blood 141(3), 285\u2013294. https:\/\/doi.org\/10.1182\/blood.2022017023 (2023).","journal-title":"Blood"},{"issue":"Supplement 1","key":"80674_CR14","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1182\/blood-2022-156306","volume":"140","author":"JA Kremer","year":"2022","unstructured":"Kremer, J. A. et al. The role of ADAMTS13 activity levels on disease exacerbation or relapse in patients with immune-mediated thrombotic thrombocytopenic purpura: post hoc analysis of the phase 3 HERCULES and post-HERCULES studies. Blood 140(Supplement 1), 5651\u20135653. https:\/\/doi.org\/10.1182\/blood-2022-156306 (2022).","journal-title":"Blood"},{"issue":"13","key":"80674_CR15","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2019001056","volume":"134","author":"H Upreti","year":"2019","unstructured":"Upreti, H. et al. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood 134(13), 1037\u20131045. https:\/\/doi.org\/10.1182\/blood.2019001056 (2019).","journal-title":"Blood"},{"issue":"31","key":"80674_CR16","doi-asserted-by":"publisher","first-page":"9620","DOI":"10.1073\/pnas.1512561112","volume":"112","author":"VC Casina","year":"2015","unstructured":"Casina, V. C. et al. High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome. Proc. Nat. Acad Sci 112(31), 9620\u20139625. https:\/\/doi.org\/10.1073\/pnas.1512561112 (2015).","journal-title":"Proc. Nat. Acad Sci"},{"issue":"2","key":"80674_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1586\/17474086.2016.1122515","volume":"9","author":"C Tersteeg","year":"2015","unstructured":"Tersteeg, C. et al. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura \u2013 current perspectives and new treatment strategies. Expert Rev. Hematol. 9(2), 209\u2013221. https:\/\/doi.org\/10.1586\/17474086.2016.1122515 (2015).","journal-title":"Expert Rev. Hematol."},{"issue":"9","key":"80674_CR18","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","volume":"169","author":"WFD Acqua","year":"2002","unstructured":"Acqua, W. F. D. et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol. 169(9), 5171\u20135180. https:\/\/doi.org\/10.4049\/jimmunol.169.9.5171 (2002).","journal-title":"J. Immunol."},{"issue":"33","key":"80674_CR19","doi-asserted-by":"publisher","first-page":"23514","DOI":"10.1074\/jbc.M604292200","volume":"281","author":"WF Dall\u2019Acqua","year":"2006","unstructured":"Dall\u2019Acqua, W. F., Kiener, P. A. & Herren, W. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281(33), 23514\u201323524. https:\/\/doi.org\/10.1074\/jbc.M604292200 (2006).","journal-title":"J. Biol. Chem."},{"issue":"33","key":"80674_CR20","doi-asserted-by":"publisher","first-page":"29428","DOI":"10.1074\/jbc.M505513200","volume":"280","author":"J Ai","year":"2005","unstructured":"Ai, J., Smith, P., Wang, S., Ping Zhang, X. & Zheng, L. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J. Biol. Chem. 280(33), 29428\u201329434. https:\/\/doi.org\/10.1074\/jbc.M505513200 (2005).","journal-title":"J. Biol. Chem."},{"issue":"10","key":"80674_CR21","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/emmm.201201379","volume":"4","author":"DM Czajkowsky","year":"2012","unstructured":"Czajkowsky, D. M., Jun, H., Shao, Z. & Pleass, R. J. Fc\u2010fusion proteins: new developments and future perspectives. EMBO Mol. Med. 4(10), 1015\u20131028. https:\/\/doi.org\/10.1002\/emmm.201201379 (2012).","journal-title":"EMBO Mol. Med."},{"issue":"6","key":"80674_CR22","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.3324\/haematol.2019.219063","volume":"104","author":"L Zafrani","year":"2019","unstructured":"Zafrani, L. et al. Transfer of ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura via kidney transplantation. Haematologica 104(6), e277\u2013e280. https:\/\/doi.org\/10.3324\/haematol.2019.219063 (2019).","journal-title":"Haematologica"},{"issue":"11","key":"80674_CR23","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1111\/jth.13137","volume":"13","author":"B Plaimauer","year":"2015","unstructured":"Plaimauer, B. et al. Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS\u201013 activity levels in inhibitor\u2010treated rats by the use of defined doses of recombinant ADAMTS\u201013. J. Thromb. Haemost. 13(11), 2053\u20132062. https:\/\/doi.org\/10.1111\/jth.13137 (2015).","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"80674_CR24","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/j.jtha.2023.02.011","volume":"21","author":"MI Underwood","year":"2023","unstructured":"Underwood, M. I., Alwan, F., Thomas, M. R., Scully, M. A. & Crawley, J. T. B. Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 21(6), 1544\u20131552. https:\/\/doi.org\/10.1016\/j.jtha.2023.02.011 (2023).","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"80674_CR25","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.ebiom.2015.06.007","volume":"2","author":"MR Thomas","year":"2015","unstructured":"Thomas, M. R., de Groot, R., Scully, M. A. & Crawley, J. T. B. Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. EBioMedicine 2(8), 942\u2013952. https:\/\/doi.org\/10.1016\/j.ebiom.2015.06.007 (2015).","journal-title":"EBioMedicine"},{"issue":"20","key":"80674_CR26","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","volume":"132","author":"M Jestin","year":"2018","unstructured":"Jestin, M. et al. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood 132(20), 2143\u20132153. https:\/\/doi.org\/10.1182\/blood-2018-04-840090 (2018).","journal-title":"Blood"},{"issue":"11","key":"80674_CR27","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1161\/ATVBAHA.115.306014","volume":"35","author":"C Tersteeg","year":"2015","unstructured":"Tersteeg, C. et al. Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura. Arteriosclerosis, Thrombosis, Vasc. Biol. 35(11), 2336\u20132342. https:\/\/doi.org\/10.1161\/ATVBAHA.115.306014 (2015).","journal-title":"Arteriosclerosis, Thrombosis, Vasc. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80674-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80674-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80674-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T03:01:49Z","timestamp":1736564509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80674-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["80674"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-80674-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"9 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HK, GC, SK, YK, YL, CL, and HJN are inventors on a patent application regarding GC1126A. HK, GC, SK, JMP, YK, YL, CL, and HJN were employed by GC Biopharma Corp. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1613"}}